“Cutting-edge Regenerative Medicine” symposium

EBERS’ CEO, Pedro Moreo, participated in the symposium on “Cutting-edge Regenerative Medicine” organized by Clínica Universidad de Navarra and CIMA research institute. He gave his view on the current situation of organ transplantation and presented the latest results obtained in the NORMOPERF (normoperf.eu) project financed by the European Commission.



Annual meeting of the BRAVE EU project

This week it was celebrated the annual meeting of the BRAVE project (projectbrave.eu, @brav3_eu), led by Dr. Felipe Prósper from Clínica Universidad de Navarra. It was great to see and meet in person the rest of partners of the consortium and discover how much progress has been done so far. On EBERS’ side, it was exciting to show to the partners the new cell culture bioreactor that has been designed in collaboration with Leartiker and Boston Scientific, which is ready for the first cell culture validation tests.


Training and demonstration session in Hospital Clínic in Barcelona

Hospital Clínic in Barcelona is one of the participants of our upcoming clinical study on kidney normothermic perfusion. Members of the technical of team of EBERS traveled to Barcelona to train the new users of the device, which included nephrologists, urologists and several other members of the Transplant Coordination Unit of the hospital. The interest of Hospital Clínic in the ARK normothermic perfusion system of EBERS goes beyond the clinical study, as several of their research projects will also benefit from normothermic perfusion.

Clínic 1Clínic 2Clínic 3

EBERS at the ESOT 2021 congress in Milan

The ARK normothermic perfusion system from EBERS was showcased during the TERMIS-AM conference that took place on August 29th-1st September in Milan, Italy. The company was present with a stand in the commercial exhibition of the conference. In addition, the company also participated in the Machine Perfusion Lab, which included two hands-off demonstration sessions where delegates of the congress had the possibility of seeing the ARK Kidney device in normal operation with porcine kidneys. The company was represented by its CEO, Pedro Moreo, and CTO, Víctor Alastrué.